What is the appropriate evaluation for hematuria in a 36-year-old male?

Evaluation of Hematuria in a 36-Year-Old Male

A 36-year-old male with hematuria requires risk stratification using the 2025 AUA/SUFU system, followed by history/physical examination, urinalysis with microscopy, serum creatinine, and then risk-appropriate imaging (CT urography for high-risk, ultrasound for intermediate-risk) plus cystoscopy based on risk factors. 1

Initial Assessment and Risk Stratification

The first critical step is determining whether this is gross hematuria (visible blood) or microhematuria (≥3 RBCs per high-power field on microscopy). This distinction fundamentally changes the evaluation pathway.

For Gross Hematuria:

• Proceed directly to full urologic workup regardless of other factors, as gross hematuria carries a 30-40% malignancy risk 2
• This includes cystoscopy and upper tract imaging (CT urography preferred)

For Microhematuria:

Apply the 2025 AUA/SUFU Risk Stratification System 1:

Key risk factors to assess:

• Smoking history (most critical - causally linked to bladder and kidney cancer)
• Age >35 years (this patient qualifies)
• Male sex (this patient qualifies)
• History of gross hematuria
• Occupational/environmental chemical exposures
• History of pelvic irradiation
• Chronic UTIs or indwelling catheters
• Family history of urologic malignancies
• Irritative voiding symptoms

Risk categories:

• Low/negligible risk: 0-0.4% malignancy rate
• Intermediate risk: 0.2-3.1% malignancy rate
• High risk: 1.3-6.3% malignancy rate

Mandatory Initial Workup (All Patients)

Before any imaging, perform 1:

1. Detailed history focusing on:

   • Tobacco exposure (pack-years, current vs former)
   • Occupational exposures (dyes, chemicals, rubber industry)
   • Irritative symptoms (urgency, frequency, dysuria)
   • Family history of urologic cancers
   • Prior urologic disease or procedures

2. Physical examination including:

   • Blood pressure measurement
   • Abdominal/flank examination
   • Digital rectal exam (assess prostate)

3. Laboratory studies:

   • Urinalysis with microscopy (confirm ≥3 RBCs/HPF)
   • Serum creatinine (assess for renal parenchymal disease)
   • Urine culture if infection suspected

Exclude Benign Causes First

Do not proceed with full hematuria workup if 2:

• Recent vigorous exercise
• Active urinary tract infection (treat first, then repeat UA)
• Recent urologic procedure or trauma
• Identified benign cause with no risk factors

If UTI suspected, obtain urine culture before antibiotics, treat infection, then repeat urinalysis. If hematuria resolves and patient has no risk factors, extensive workup may not be needed 2.

Risk-Stratified Imaging Approach

High-Risk Patients:

CT urography is the gold standard 2

• Includes unenhanced phase (for stones), nephrographic phase, and excretory phase (≥5 minutes post-contrast)
• Thin-slice acquisition with multiplanar reconstructions
• Evaluates both upper tracts and bladder
• Plus cystoscopy (essential - most cancers are bladder cancers best detected by cystoscopy) 1

Intermediate-Risk Patients:

Ultrasound kidneys is reasonable first-line imaging 1

• Less radiation exposure
• Can detect masses, stones, hydronephrosis
• Plus cystoscopy for bladder evaluation
• Consider CT urography if ultrasound abnormal or high clinical suspicion

Low-Risk Patients:

Shared decision-making regarding extent of workup 1

• May consider repeat urinalysis in 6 months
• Imaging may not be routinely indicated if truly low-risk
• However, at age 36 with male sex, most patients will fall into at least intermediate risk

Critical Pitfalls to Avoid

1. Do not skip cystoscopy in favor of imaging alone - bladder cancer is the most common malignancy found in hematuria evaluations, and imaging misses many bladder lesions 1

2. Anticoagulation is NOT an excuse to skip workup - patients on anticoagulants require the same evaluation as those not anticoagulated 2

3. Do not use urine cytology or urine markers in initial evaluation - these are not recommended by current guidelines for initial workup 1

4. Renal parenchymal disease requires concurrent nephrology evaluation but does not preclude urologic evaluation 2

Practical Algorithm for This 36-Year-Old Male

1. Confirm hematuria: Microscopy showing ≥3 RBCs/HPF on properly collected specimen
2. Exclude infection: UA/culture if indicated
3. Assess risk factors: Detailed smoking history, occupational exposures, symptoms
4. Obtain serum creatinine and blood pressure
5. If intermediate/high risk: CT urography + cystoscopy
6. If low risk (unlikely given age/sex): Shared decision-making about repeat UA vs imaging
7. Follow-up required even if initial evaluation negative 1

The 2025 AUA/SUFU guidelines represent the most current evidence-based approach, superseding older recommendations and providing a structured risk-stratification system that balances cancer detection against overutilization of resources 1.